ATE307204T1 - Tumor-nekrose-faktor ähnliches ligand - Google Patents

Tumor-nekrose-faktor ähnliches ligand

Info

Publication number
ATE307204T1
ATE307204T1 AT97935334T AT97935334T ATE307204T1 AT E307204 T1 ATE307204 T1 AT E307204T1 AT 97935334 T AT97935334 T AT 97935334T AT 97935334 T AT97935334 T AT 97935334T AT E307204 T1 ATE307204 T1 AT E307204T1
Authority
AT
Austria
Prior art keywords
necrosis factor
tumor
factor similar
similar ligand
ligand
Prior art date
Application number
AT97935334T
Other languages
English (en)
Inventor
Yves Chicheportiche
Jeffrey L Browning
Original Assignee
Biogen Idec Inc
Faculty Of Medicine Of The Uni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Faculty Of Medicine Of The Uni filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE307204T1 publication Critical patent/ATE307204T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT97935334T 1996-08-07 1997-08-07 Tumor-nekrose-faktor ähnliches ligand ATE307204T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2354196P 1996-08-07 1996-08-07
US2851596P 1996-10-18 1996-10-18
US4082097P 1997-03-18 1997-03-18
PCT/US1997/013945 WO1998005783A1 (en) 1996-08-07 1997-08-07 A tumor necrosis factor related ligand

Publications (1)

Publication Number Publication Date
ATE307204T1 true ATE307204T1 (de) 2005-11-15

Family

ID=27362110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97935334T ATE307204T1 (de) 1996-08-07 1997-08-07 Tumor-nekrose-faktor ähnliches ligand

Country Status (25)

Country Link
EP (2) EP1591530B8 (de)
JP (3) JP4161084B2 (de)
KR (1) KR100543730B1 (de)
CN (2) CN101024831A (de)
AT (1) ATE307204T1 (de)
AU (1) AU736289B2 (de)
BG (1) BG64779B1 (de)
BR (1) BR9711046A (de)
CA (1) CA2262756C (de)
CZ (1) CZ297387B6 (de)
DE (1) DE69734397T2 (de)
DK (1) DK0956351T3 (de)
EA (1) EA003187B1 (de)
EE (1) EE05276B1 (de)
ES (1) ES2251737T3 (de)
HU (1) HU226787B1 (de)
IL (1) IL128407A (de)
IS (1) IS2606B (de)
NO (2) NO326967B1 (de)
NZ (1) NZ334107A (de)
PL (1) PL188102B1 (de)
SI (1) SI0956351T1 (de)
SK (1) SK288012B6 (de)
TR (1) TR199900903T2 (de)
WO (1) WO1998005783A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9376498A (en) * 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EP1021542B1 (de) * 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
DE19829550C1 (de) * 1998-07-02 2000-01-27 Bosch Gmbh Robert Vorrichtung zum Verbinden von Bauteilen
EE200100372A (et) 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
AU784504B2 (en) * 1999-11-19 2006-04-13 Thomas V. Tittle TR3-specific binding agents and methods for their use
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
AU782067B2 (en) * 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CA2887716C (en) 2002-04-09 2017-01-24 Biogen Idec Ma Inc. Methods for treating tweak-related conditions
US20070010658A1 (en) * 2002-10-29 2007-01-11 Holtet Thor L Trimeric binding proteins for trimeric cytokines
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
DK1888113T3 (da) 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
PE20131411A1 (es) 2010-10-05 2013-12-16 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
EP2834273B1 (de) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispezifische antikörper gegen menschliches tweak und menschliches il17, und deren verwendungen
CA3041451A1 (en) * 2016-10-24 2018-05-03 Biois Co.,Ltd Tnf-.alpha.-binding aptamer, and therapeutic use for same
WO2019203904A1 (en) * 2018-04-20 2019-10-24 Academia Sinica Tnf-targeting aptamers and uses thereof for treatment or diagnosing tnf-related inflammatory diseases
WO2022217283A1 (en) 2021-04-08 2022-10-13 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal decline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
IE902820A1 (en) 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
JPH05310784A (ja) 1991-09-04 1993-11-22 Merck & Co Inc ヒト乳頭腫ウイルスタンパク質と網膜芽細胞腫遺伝子タンパク質との結合のペプチド阻害剤

Also Published As

Publication number Publication date
IS4967A (is) 1999-02-05
SI0956351T1 (sl) 2006-02-28
CN1232503A (zh) 1999-10-20
IL128407A0 (en) 2000-01-31
PL188102B1 (pl) 2004-12-31
HK1025994A1 (en) 2000-12-01
JP4161084B2 (ja) 2008-10-08
EP1591530B1 (de) 2015-02-25
BG64779B1 (bg) 2006-03-31
CZ40399A3 (cs) 1999-08-11
EP0956351B1 (de) 2005-10-19
CA2262756A1 (en) 1998-02-12
NO326967B1 (no) 2009-03-23
EP0956351A1 (de) 1999-11-17
CN101024831A (zh) 2007-08-29
JP4411330B2 (ja) 2010-02-10
BG103169A (en) 2000-06-30
DE69734397T2 (de) 2006-07-06
HUP9903921A2 (hu) 2000-03-28
EA003187B1 (ru) 2003-02-27
EP1591530A3 (de) 2009-04-08
CN1308451C (zh) 2007-04-04
PL331583A1 (en) 1999-07-19
NO990550L (no) 1999-04-06
SK288012B6 (sk) 2012-10-02
JP2001505407A (ja) 2001-04-24
IL128407A (en) 2007-07-24
BR9711046A (pt) 2000-01-11
HUP9903921A3 (en) 2000-08-28
CA2262756C (en) 2012-06-12
DE69734397D1 (de) 2006-03-02
NO990550D0 (no) 1999-02-05
SK15799A3 (en) 2000-03-13
TR199900903T2 (xx) 1999-06-21
JP2007204480A (ja) 2007-08-16
EE05276B1 (et) 2010-02-15
WO1998005783A1 (en) 1998-02-12
NZ334107A (en) 2000-06-23
ES2251737T3 (es) 2006-05-01
AU3829497A (en) 1998-02-25
EE9900043A (et) 1999-08-16
EA199900187A1 (ru) 1999-08-26
DK0956351T3 (da) 2006-02-20
EP1591530B8 (de) 2015-04-22
AU736289B2 (en) 2001-07-26
IS2606B (is) 2010-04-15
JP2009183294A (ja) 2009-08-20
NO20084906L (no) 1999-04-06
KR20000029877A (ko) 2000-05-25
CZ297387B6 (cs) 2006-11-15
EP1591530A2 (de) 2005-11-02
HU226787B1 (en) 2009-10-28
KR100543730B1 (ko) 2006-01-23

Similar Documents

Publication Publication Date Title
ATE307204T1 (de) Tumor-nekrose-faktor ähnliches ligand
WO1999012965A3 (en) April- a novel protein with growth effects
FI941459A7 (fi) Tuumorinekroositekijän muteiineja
WO1999012964A3 (en) Kay - a novel immune system protein
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
ATA188592A (de) Alkyl-bisacylphosphinoxide, diese enthaltende zusammensetzungen und ihre verwendung
FI944516L (fi) Fuusioproteiineja, jotka sisältävät kasvainkuoliotekijän reseptoria
EP0601695A3 (de) Operationstisch.
DE59005251D1 (de) Selbstfahrender Mähdrescher.
FR2701264B1 (fr) Muteines de facteur de necrose tumorale.
AU7705098A (en) Human tumor necrosis factor receptor-like protein 8
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
DE68905750D1 (de) Taumelscheibenkompressor.
NO921674L (no) E. coli sekresjonsstammer
FI920845A0 (fi) Farmaceutiska kompositioner innehaollande interleukin-2.
DE59005057D1 (de) Mischgaspumpen-Antrieb.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
FI20000833L (fi) Kasvainkuoliotekijä-alfa- ja kasvainkuoliotekijä-beta- reseptoreita
ES1014575Y (es) Pantalla luminosa compacta, estanca, perfeccionada.
ES1020875Y (es) Futbolin.
ES1027112Y (es) Rodillo pera amasar perfeccionado.
ATE102224T1 (de) Modifizierte polytetrafluoraethylenharze und damit hergestellte zusammensetzungen.
DE69015573D1 (de) Kohlenstoffmolekularsieb.
ES1025128Y (es) Luminaria perfeccionada.
ES1024201Y (es) Luminaria perfeccionada.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0956351

Country of ref document: EP